HK1218882A1 - 用於治療神經退化疾病和其它疾病的組合治療劑和方法 - Google Patents

用於治療神經退化疾病和其它疾病的組合治療劑和方法

Info

Publication number
HK1218882A1
HK1218882A1 HK16106972.1A HK16106972A HK1218882A1 HK 1218882 A1 HK1218882 A1 HK 1218882A1 HK 16106972 A HK16106972 A HK 16106972A HK 1218882 A1 HK1218882 A1 HK 1218882A1
Authority
HK
Hong Kong
Prior art keywords
neurodegenerative
diseases
treatment
methods
combination therapeutics
Prior art date
Application number
HK16106972.1A
Other languages
English (en)
Inventor
Trevor Percival Castor
Original Assignee
Aphios Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphios Corp filed Critical Aphios Corp
Publication of HK1218882A1 publication Critical patent/HK1218882A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16106972.1A 2012-11-28 2016-06-17 用於治療神經退化疾病和其它疾病的組合治療劑和方法 HK1218882A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730761P 2012-11-28 2012-11-28
PCT/US2013/072076 WO2014085494A1 (en) 2012-11-28 2013-11-26 Combination therapeutics and methods for the treatment of neurodegenerative and other diseases

Publications (1)

Publication Number Publication Date
HK1218882A1 true HK1218882A1 (zh) 2017-03-17

Family

ID=50828429

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106972.1A HK1218882A1 (zh) 2012-11-28 2016-06-17 用於治療神經退化疾病和其它疾病的組合治療劑和方法

Country Status (6)

Country Link
US (1) US10828276B2 (zh)
EP (1) EP2925314B1 (zh)
JP (1) JP6579956B2 (zh)
CN (1) CN105228614A (zh)
HK (1) HK1218882A1 (zh)
WO (1) WO2014085494A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
CN105228614A (zh) 2012-11-28 2016-01-06 阿菲欧斯公司 用于治疗神经退化疾病和其它疾病的组合治疗剂和方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8
US5440055A (en) 1993-03-12 1995-08-08 Aphios Corporation Method and apparatus for extracting taxol from source materials
US5854064A (en) 1996-07-31 1998-12-29 Aphios Corporation Methods for fractionation of biologically-derived materials
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
AU2195297A (en) 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US6228843B1 (en) 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
US6624189B2 (en) 1999-11-30 2003-09-23 The Board Of Trustees Of The Leland Stanford Junior University Byrostatin analogues, synthetic methods and uses
WO2002028387A1 (en) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US20080004332A1 (en) 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
WO2003086369A2 (en) * 2002-04-05 2003-10-23 Valorisation-Recherche, Societe En Commandite Stealthy polymeric biodegradable nanospheres and uses thereof
AU2003281214A1 (en) 2002-07-02 2004-01-23 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPAlpha SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
KR101215284B1 (ko) * 2002-07-02 2012-12-26 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 브리오스타틴형 화합물을 사용한 ｓＡＰＰα 분비의 증진 및 인지 개선을 위한 수단으로서의 ＰＫＣ 활성화
EP1569616A2 (en) 2002-12-04 2005-09-07 Technologies Biolactis Inc. An exopolysaccharides delivery system for active molecules
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US7871358B2 (en) * 2005-10-14 2011-01-18 Gary Graham Height adjustable shuttle treatment table/exercise device method and apparatus
CN104758253A (zh) 2006-01-24 2015-07-08 安迅生物制药公司 大分子微球的制备技术
CA2674773A1 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
US8071119B2 (en) * 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
US8497385B2 (en) 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
US20100168219A1 (en) 2008-12-31 2010-07-01 Jonathan Steven Alexander Chronic inflammation and transplantation
US20120309818A1 (en) 2007-12-31 2012-12-06 Jonathan Steven Alexander Chronic inflammation and transplantation
WO2009129361A2 (en) 2008-04-16 2009-10-22 University Of Utah Research Foundation Macrocyclic compounds and methods of making and using thereof
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2010014990A2 (en) * 2008-08-01 2010-02-04 The Board Of Trustees Of The University Of Illinois Method of promoting neurogenesis by modulating secretase activities
US20100166806A1 (en) 2008-12-29 2010-07-01 Aphios Corporation Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency
US20120077851A1 (en) * 2009-06-09 2012-03-29 Medolution Limited Urea Derivatives as Kinase Inhibitors
EP3967299A1 (en) * 2011-11-13 2022-03-16 Cognitive Research Enterprises, Inc. Pkc activators and combinations thereof
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
CN109331013B (zh) 2012-11-27 2022-02-01 阿菲欧斯公司 苔藓素组合物、其制备方法和用途
CN105228614A (zh) 2012-11-28 2016-01-06 阿菲欧斯公司 用于治疗神经退化疾病和其它疾病的组合治疗剂和方法

Also Published As

Publication number Publication date
US20150297555A1 (en) 2015-10-22
EP2925314A4 (en) 2016-06-01
US10828276B2 (en) 2020-11-10
EP2925314A1 (en) 2015-10-07
WO2014085494A8 (en) 2015-04-23
CN105228614A (zh) 2016-01-06
JP2016501225A (ja) 2016-01-18
WO2014085494A1 (en) 2014-06-05
EP2925314B1 (en) 2020-04-01
JP6579956B2 (ja) 2019-09-25

Similar Documents

Publication Publication Date Title
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
IL269852B (en) Combined treatments and uses for the treatment of demyelination disorders
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
EP2852388A4 (en) COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
IL269377B (en) Means and methods for diagnostics and therapeutics of diseases
IL225246A0 (en) Methods for speeding up the restoration of skin normality and for treatment of impetigo
EP2953950A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
HK1198909A1 (zh) 用於治療肝臟疾病和障礙的組合物和方法
EP2906583A4 (en) PEPTIDES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
HK1220352A1 (zh) 和神經變性疾病的治療
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
HK1215548A1 (zh) 用於治療神經變性疾病的方法和組合物
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
HK1216721A1 (zh) 治療肝臟疾病或病狀的用途和方法
EP2739304A4 (en) PARTICLES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
HK1218882A1 (zh) 用於治療神經退化疾病和其它疾病的組合治療劑和方法
EP2925755A4 (en) NEUROPROTECTIVE AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201408065B (en) Compositions and methods for the treatment of diabetes
EP2800554A4 (en) METHOD FOR TREATING MULTIPLE SCLEROSIS AND OTHER DEMYELINISING DISEASES
GB201317550D0 (en) Use of Enalaprilat for treatment of neurodegenerative diseases